Published in JAMA on December 09, 2008
S0000 Selenium and Vitamin E in Preventing Prostate Cancer (SELECT) | NCT00006392
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev (2012) 2.71
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Anticancer vitamins du Jour--The ABCED's so far. Am J Epidemiol (2010) 2.30
Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance--next, cause. JAMA (2008) 2.24
Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer (2010) 2.15
Selenium for preventing cancer. Cochrane Database Syst Rev (2011) 2.11
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol (2015) 2.06
Eating fish and risk of type 2 diabetes: A population-based, prospective follow-up study. Diabetes Care (2009) 2.03
Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med (2011) 1.93
Regulation and function of selenoproteins in human disease. Biochem J (2009) 1.93
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol (2009) 1.91
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84
Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol (2010) 1.82
Regulation of Nrf2-an update. Free Radic Biol Med (2013) 1.81
Health-promoting components of fruits and vegetables in the diet. Adv Nutr (2013) 1.68
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Dietary supplements and cancer prevention: balancing potential benefits against proven harms. J Natl Cancer Inst (2012) 1.60
Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis (2009) 1.59
Serum antioxidant nutrients, vitamin A, and mortality in U.S. Adults. Cancer Epidemiol Biomarkers Prev (2013) 1.58
Mitohormesis. Cell Metab (2014) 1.57
Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal (2011) 1.57
Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. Cancer Prev Res (Phila) (2014) 1.57
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
The human selenoproteome: recent insights into functions and regulation. Cell Mol Life Sci (2009) 1.50
The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal (2012) 1.47
Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst (2014) 1.44
Trends in Dietary Supplement Use Among US Adults From 1999-2012. JAMA (2016) 1.42
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) (2011) 1.38
Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ Health Perspect (2009) 1.37
Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal (2012) 1.36
Selenoproteins: molecular pathways and physiological roles. Physiol Rev (2014) 1.34
Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.33
Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) (2009) 1.30
Selenium and selenocysteine: roles in cancer, health, and development. Trends Biochem Sci (2014) 1.30
Mitochondrial oxidative stress and mammalian healthspan. Mech Ageing Dev (2010) 1.29
Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim Biophys Acta (2009) 1.29
Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr (2010) 1.26
Serum selenium concentrations and hypertension in the US Population. Circ Cardiovasc Qual Outcomes (2009) 1.24
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol (2010) 1.21
ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol (2011) 1.21
Cancer chemoprevention: a rapidly evolving field. Br J Cancer (2013) 1.20
Higher selenium status is associated with adverse blood lipid profile in British adults. J Nutr (2009) 1.20
Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl (2012) 1.19
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol (2009) 1.17
Selenium for preventing cancer. Cochrane Database Syst Rev (2014) 1.17
Determinants of selenium status in healthy adults. Nutr J (2011) 1.16
Dietary selenium modulates activation and differentiation of CD4+ T cells in mice through a mechanism involving cellular free thiols. J Nutr (2010) 1.16
A gamma-tocopherol-rich mixture of tocopherols inhibits chemically induced lung tumorigenesis in A/J mice and xenograft tumor growth. Carcinogenesis (2010) 1.16
The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv (2009) 1.16
Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate (2012) 1.15
Molecular consequences of genetic variations in the glutathione peroxidase 1 selenoenzyme. Cancer Res (2009) 1.15
Vitamin and mineral supplements: do we really need them? Int J Prev Med (2012) 1.14
Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol (2010) 1.14
Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet (2011) 1.14
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14
Selenium and lung cancer: a systematic review and meta analysis. PLoS One (2011) 1.13
Cancer prevention research - then and now. Nat Rev Cancer (2009) 1.12
Redox control of liver function in health and disease. Antioxid Redox Signal (2010) 1.12
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2013) 1.12
Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. J Urol (2011) 1.11
Fish oil, selenium and mercury in relation to incidence of hypertension: a 20-year follow-up study. J Intern Med (2011) 1.11
Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. Carcinogenesis (2010) 1.11
Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev (2009) 1.11
Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol (2012) 1.10
A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health (2010) 1.09
Is statin use associated with prostate cancer aggressiveness? BJU Int (2009) 1.09
Prostate cancer: is it time to expand the research focus to early-life exposures? Nat Rev Cancer (2013) 1.08
Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2014) 1.07
δ-tocopherol is more active than α - or γ -tocopherol in inhibiting lung tumorigenesis in vivo. Cancer Prev Res (Phila) (2011) 1.07
How does the macula protect itself from oxidative stress? Mol Aspects Med (2012) 1.06
New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila) (2013) 1.05
Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int J Cancer (2010) 1.05
Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal (2011) 1.04
Selenium compounds activate early barriers of tumorigenesis. J Biol Chem (2010) 1.04
Selenium and vitamin E supplementation for cancer prevention. JAMA (2009) 1.04
Risk factors for prostate cancer. Nat Clin Pract Urol (2009) 1.03
High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr (2010) 1.03
Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Atherosclerosis (2010) 1.03
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy. Int J Mol Sci (2012) 1.02
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol (2014) 1.02
Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis. Dose Response (2009) 1.02
MicroRNA, nutrition, and cancer prevention. Adv Nutr (2011) 1.02
Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci (2011) 1.01
Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res (Phila) (2009) 1.01
Selenium regulation of the selenoprotein and nonselenoprotein transcriptomes in rodents. Adv Nutr (2011) 1.01
Does vitamin E prevent or promote cancer? Cancer Prev Res (Phila) (2012) 1.01
Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol (2014) 1.01
Evaluation of web-based, self-administered, graphical food frequency questionnaire. J Acad Nutr Diet (2014) 1.00
A γ-tocopherol-rich mixture of tocopherols maintains Nrf2 expression in prostate tumors of TRAMP mice via epigenetic inhibition of CpG methylation. J Nutr (2012) 1.00
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 11.87
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst (1993) 8.30
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (2007) 7.11
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA (2000) 6.37
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst (2000) 4.89
Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst (1998) 4.72
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med (2007) 3.67
A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst (2004) 3.32
Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev (2002) 3.15
The prevention of prostate cancer--the dilemma continues. N Engl J Med (2003) 3.00
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst (1998) 2.97
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst (2006) 2.48
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res (2000) 2.06
Serum selenium and diabetes in U.S. adults. Diabetes Care (2007) 1.96
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
Cancer chemoprevention: progress and promise. J Natl Cancer Inst (1998) 1.87
Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res (2001) 1.74
Science peels the onion of selenium effects on prostate carcinogenesis. J Natl Cancer Inst (2004) 1.66
Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer (2004) 1.60
Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev (2000) 1.51
Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst (2005) 1.44
How much vitamin E? ... Just enough! Am J Clin Nutr (2006) 1.35
Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett (1998) 1.32
Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res (2001) 1.30
Toenail selenium and cardiovascular disease in men with diabetes. J Am Coll Nutr (2005) 1.29
Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol (1999) 1.14
Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol (2002) 1.13
Vitamin E in the prevention of prostate cancer: where are we today? J Natl Cancer Inst (2006) 1.05
High-grade prostate cancer and the prostate cancer prevention trial. Cancer Prev Res (Phila) (2008) 1.03
Selenium, vitamin E, and prostate cancer--ready for prime time? J Natl Cancer Inst (1998) 1.02
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 24.36
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22